METTLER TOLEDO INTERNATIONAL INC/ Q1 FY2025 earnings call

Business Start

• Good start to the year with solid growth in laboratory business, excluding delayed shipments in Q1 2024. Strong margin expansion led to better-than-expected earnings.

Tariffs Impact

• Ongoing global trade disputes and tariffs increased uncertainty. Estimated annualized cross-incremental global tariff costs of $115 million, with mitigation actions to offset costs next year.

Operational Excellence

• Confident in strong culture of operational excellence and agile team. Benefit from innovative product portfolio and strategic programs.

Business Segments

• Laboratory: Solid growth, recent innovations like titrators and thermal analysis instruments, strong in process analytics.
• Industrial: Product inspection business growth offset challenging market conditions, innovation investments well received.
• Core Industrial: Sales down slightly due to mixed industry conditions, engaging with customers with cost-saving solutions.
• Food Retail: Decline as expected.

Geography

• The Americas: Underlying sales growth led by process analytics and product inspection, partially offset by lower core industrial sales.
• Europe: Underlying sales growth across businesses except retail, benefited from innovative portfolio and Spinnaker programs.
• Asia rest of the world: Results as expected, modest growth, soft market conditions in China.

Sales in the quarter were $884 million, with a 3% decrease in local currency. Excluding shipping delays, local currency sales grew 3%. On a U.S. dollar basis, sales declined 5%. By region, local currency sales declined 1% in The Americas, 7% in Europe, 2% in Asia rest of the world, and were flat in China. Excluding shipping delay recoveries, The Americas grew 3%, Europe 4%, Asia rest of the world 3% (including 3% growth in China). By product area, laboratory sales decreased 3%, industrial declined 1% (core industrial down 6%, product inspection up 8%), food retail declined 12%. Excluding shipping recoveries, laboratory grew 5%, industrial 2% (core industrial down 2%, product inspection up 8%), food retail declined 5%. Service sales increased 6% in local currency. Gross margin was 59.5% (up 30 basis points, 90 basis points excluding shipping delays). Adjusted operating profit was $237 million (down 11% from prior year). Adjusted EPS was $8.19 (down 8% from prior year). Adjusted free cash flow was $180 million (up 1% per share).

Second Quarter 2025

• Local currency sales expected to grow 0% to 1%. Operating margin expected to decrease 170 basis points at midpoint (down 70 basis points excluding tariffs). Adjusted EPS range $9.45 to $9.70 (down 2% to up 1%).

Full Year 2025

• Local currency sales growth forecast 1% to 2% (up 2.5% to 3.5% excluding shipping delays). Operating margin expected to decrease 130 basis points at midpoint (slightly up excluding tariffs and prior year shipping delays). Adjusted EPS range $41.25 to $42 (down from previous guidance $42.35 to $43).

Tariff Impact

• Gross headwind of ~7% from tariffs, offset by mitigation actions, resulting in net headwind of ~2%.

Other Details

• Total amortization ~$72 million, interest expense $72 million, other income ~$9 million, tax rate 19%, free cash flow ~$860 million, share repurchases ~$875 million.

• Tariffs and Geopolitical Tensions: Ongoing global trade disputes and tariffs increase uncertainty in customer demand. Potential for new or retaliatory tariffs not factored into guidance.
• Supply Chain Delays: Third-party logistics provider delays impacted prior results, reducing sales, operating margin, and adjusted EPS.
• Market Conditions: Slower market conditions than expected, especially in China, affecting volume growth.

Q: Dan Leonard of UBS on China revenue growth forecast A: Shawn Vadala said China expected down slightly in full year, Q2 down low to mid-single digit. Lab up low single digit, industrial down low single digit in full year.

Q: Patrick Donnelly of Citi on tariffs impact and mitigation A: Shawn Vadala discussed supply chain optimization, pricing increases, and surcharges to mitigate tariff impact.

Q: Jack Meehan of Nephron Research on customer behavior and tariffs A: Patrick Kaltenbach said no significant pull forward of orders due to tariffs.

Q: Brandon Couillard of Wells Fargo on manufacturing in China and free cash flow A: Shawn Vadala discussed manufacturing in China supporting local markets and free cash flow management.

Q: Vijay Kumar of Evercore ISI on guidance cadence and tariff impact A: Shawn Vadala explained Q2 guidance and tariff impact on EPS.

Q: Matt Sykes of Goldman on China competitive landscape and services growth A: Patrick Kaltenbach and Shawn Vadala discussed competitive positioning in China and services growth.

Q: Avery of Wolfe Research on margin mix and OpEx A: Shawn Vadala discussed gross margin mix and OpEx related to tariffs and preparation.

Q: Rachel Vatnsdal of JPMorgan on customer caution and margin cadence A: Shawn Vadala discussed customer caution impact on Q2 and margin mitigation timing.

Q: Royston of Bank of America on fiscal 2025 guide reduction and U.S. NIH exposure A: Shawn Vadala explained guide reduction factors and small NIH exposure impact.

Q: Tycho Peterson of Jefferies on lab pharma customers and China manufacturing share A: Patrick Kaltenbach and Shawn Vadala discussed pharma customer engagement and China manufacturing competitive advantage.

Q: Catherine Schulte of Baird on tariffs and capital deployment A: Shawn Vadala discussed tariff exposure from Switzerland and consistent buyback plan.

Q: Josh Waldman of Cleveland Research on core industrial softness and bioproduction OEMs A: Patrick Kaltenbach and Shawn Vadala discussed core industrial softness in China and bioproduction OEM business tracking